Forbes -
1 Jul 2021 15:00

The stock price of Nevro, a medical devices company, has seen a 7% drop over the last five trading days, despite the company announcing positive findings from its spinal cord stimulation clinical trials for painful diabetic neuropathy. While NVRO stock did respond positively to this...
Share this Article